𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A double-blind, placebo controlled, multicentre study of tacrine for alzheimer's disease

✍ Scribed by Philip C. Wood; Professor C. Mark Castleden

Publisher
John Wiley and Sons
Year
1994
Tongue
English
Weight
527 KB
Volume
9
Category
Article
ISSN
0885-6230

No coin nor oath required. For personal study only.

✦ Synopsis

The present study was designed to determine whether oral tacrine (tetrahydroaminoacridine, THA) improves the symptoms of patients with mild to moderate Alzheimer's disease. The study was a multicentre, randomized doubleblind, placebo controlled, parallel group study with individual determination of maximum tolerated dose over a period of 12 weeks. One hundred and fifty-four patients (93 women) aged 44-92 years (mean 75) were selected as having probable Alzheimer's disease as defined by NINCDS-ADRDA workgroup classification and a Mini-Mental State Examination score of 10 or more. Most patients were titrated to 80 mg of tacrine per day. Tacrine improved patients in clinicians' global ratings and the relatives' global rating compared to placebo (p < 0.05).

Tacrine did not significantly improve the Mini-Mental State Examination score, although as with other scores the trend favoured tacrine. There was a substantial variation in response among patients. Twelve patients in the tacrine and four in the placebo group were withdrawn from the study due to raised LFTs or adverse events. No serious sequelae resulted from these. One patient in the placebo group and two in the tacrine group died from causes which were considered unrelated to the treatment. KEY woms-Alzheimer's disease, tacrine, double-blind method, placebos.

📜 SIMILAR VOLUMES

Hypericum treatment of mild–moderate dep
Hypericum treatment of mild–moderate depression in a placebo–controlled study. A prospective, double–blind, randomized, placebo–controlled, multicentre study
✍ E. Schrader; B. Meier; A. Brattström 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB 👁 2 views

A prospective, randomized, multicentre, double-blind placebo controlled study is described which compares the ecacy and tolerability of hypericum administered as a concentrated ethanolic extract of St John's wort (ZE117) to patients with mild±moderate depression (ICD-10; F 32 . 0 mild; F 32 . 1 mode

A double-blind, placebo-controlled singl
A double-blind, placebo-controlled single dose trial of intravenous flumazenil in Alzheimer's disease
✍ Lisa Templeton; Andrew Barker; Keith Wesnes; David Wilkinson 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 203 KB 👁 2 views

Benzodiazepine agonists have been shown to reduce cognitive functioning by producing attentional de®cits similar to those produced by muscarinic antagonists. It has therefore been postulated that benzodiazepine antagonists may improve cognitive function in patients with Alzheimer's disease by indire

Risperidone for psychosis of Alzheimer's
Risperidone for psychosis of Alzheimer's disease and mixed dementia: results of a double-blind, placebo-controlled trial
✍ Henry Brodaty; David Ames; John Snowdon; Michael Woodward; Jeff Kirwan; Roger Cl 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB 👁 2 views

## Objective: To evaluate the efficacy and safety of low-dose risperidone in treating psychosis of alzheimer's disease (ad) and mixed dementia (md) in a subset of nursing-home residents who had dementia and aggression and who were participating in a randomized placebo-controlled trial of risperidon

A randomized, double-blind, placebo-cont
A randomized, double-blind, placebo-controlled trial of olsalazine for active Crohn's disease
✍ J. P. Wright; Dr. D. P. Jewell; R. Modigliani; H. Malchow 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 486 KB 👁 2 views

Olsalazine, consisting of two salicylate radicals linked by an azo-bond, is effective in the treatment of active ulcerative colitis. To test its effect in patients with mild to moderate attacks of Crohn's disease, the International Organization for the Study of Inflammatory Bowel Disease (IOIBD) des

Quetiapine treatment for behavioural and
Quetiapine treatment for behavioural and psychological symptoms of dementia in Alzheimer's disease patients: a 6-week, double-blind, placebo-controlled study
✍ D. Paleacu; Y. Barak; I. Mirecky; D. Mazeh 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 87 KB 👁 2 views

## Abstract ## Setting Treating elderly patients with Alzheimer's disease (AD) and behavioral and psychological symptoms of dementia (BPSD) is challenging due to the increased risk of iatrogenic movement disorders with old neuroleptics and the seemingly increasing risk of cardiovascular events wit